Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Target selection issues in drug discovery and development.

E A Sausville1

  • 1Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, USA. esausville@umm.edu

Journal of Chemotherapy (Florence, Italy)
|February 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Bone marrow transplantation·2016
Same author

Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.

Cell death and differentiation·2005
Same author

Geldanamycin analogs.

Journal of chemotherapy (Florence, Italy)·2005
Same author

The hollow fibre model in cancer drug screening: the NCI experience.

European journal of cancer (Oxford, England : 1990)·2004
Same author

A potential role for imaging technology in anticancer efficacy evaluations.

European journal of cancer (Oxford, England : 1990)·2004
Same author

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

The Journal of urology·2004
Same journal

Eravacycline in sepsis complicated by <i>Clostridioides difficile</i> infection: a brief case series.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol for <i>Stenotrophomonas maltophilia</i> infections: real-world evidence from a multicenter study and a comprehensive literature review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol susceptibility in carbapenem-resistant <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Stenotrophomonas maltophilia</i> isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles

New cancer treatment targets can focus on mutated oncogenes, or explore ontogenic and pharmacological targets within the tumor microenvironment. Defining a therapeutic index is key for successful cancer therapy development.

Area of Science:

  • Oncology
  • Drug Discovery
  • Molecular Biology

Background:

  • Traditional cancer treatments often target oncogenes mutated within tumors.
  • Alternative therapeutic strategies are needed to overcome treatment resistance and improve patient outcomes.
  • Novel targets may reside in molecules related to tissue of origin (ontogenic) or drug handling (pharmacological).

Purpose of the Study:

  • To explore novel target classes beyond mutated oncogenes for cancer therapy.
  • To identify strategies for targeting the tumor microenvironment.
  • To establish criteria for evaluating the therapeutic potential of new targets.

Main Methods:

  • Literature review of existing and proposed cancer therapeutic targets.
  • Analysis of ontogenic and pharmacological target classes.

Related Experiment Videos

  • Conceptual framework for defining a therapeutic index for novel targets.

    • Main Results:

    • Identified ontogenic and pharmacological targets as promising avenues for cancer treatment.
    • Highlighted the importance of the tumor microenvironment as a therapeutic target.
    • Proposed the necessity of a defined therapeutic index assay for target validation.

    Conclusions:

    • Cancer treatment strategies can be expanded by considering ontogenic, pharmacological, and tumor microenvironment targets.
    • A robust assay to define a therapeutic index is crucial for advancing novel cancer targets.
    • Further research into these alternative targets may lead to more effective cancer therapies.